Fat Grafting in Reconstructive Surgery

Fat grafting had been attempted since the late 19th century but suffered from unpredictable resorption and complications until Sidney Coleman standardized his structural fat grafting technique in the 1990s. Coleman's method emphasized atraumatic harvesting, centrifugation for purification, and precise injection in small aliquots to maximize graft-to-recipient contact and neovascularization. His landmark publications demonstrated consistent results in facial rejuvenation with predictable volume retention of 50-70%. This systematic approach transformed fat grafting from an unreliable procedure into a reproducible reconstructive tool.

The application of fat grafting to breast reconstruction raised significant oncologic safety concerns. The ASPS initially issued a position statement in 1987 cautioning against fat injection to the breast due to potential interference with mammographic cancer detection. However, large retrospective studies, particularly by Petit et al. and Kronowitz et al., involving hundreds of breast cancer patients treated with fat grafting, found no increased risk of local recurrence. The ASPS Fat Graft Task Force reviewed the evidence in 2009 and 2012 and concluded that fat grafting to the breast did not appear to increase cancer risk, though long-term data remained limited. This opened the floodgates for widespread adoption.

Research expanded into stem cell-enriched fat grafting (cell-assisted lipotransfer), which supplements fat grafts with adipose-derived stem cells (ADSCs) to potentially improve graft survival. The RESTORE-2 trial and other prospective studies showed modest improvements in volume retention with ADSC enrichment but raised ongoing questions about the safety of injecting stem cells into a cancer-treated field. Applications broadened to include hand rejuvenation, Dupuytren contracture treatment, radiation-induced tissue damage repair, and scar revision. MRI-based volumetric studies provided objective evidence of 50-80% graft retention at 1 year with optimized techniques.

The ASPS and multiple international societies now endorse fat grafting as a safe and effective adjunct in breast reconstruction, with no evidence of increased cancer recurrence risk in the current literature. Consensus statements recommend standard mammographic surveillance protocols without modification after fat grafting. The European Association of Plastic Surgeons (EURAPS) published guidelines supporting fat grafting in reconstructive and aesthetic settings. However, most societies note that long-term oncologic data beyond 10 years remains limited and ongoing surveillance is warranted.

Fat grafting has become an indispensable tool across all domains of plastic surgery. In breast reconstruction, it is used to improve contour irregularities after implant or flap reconstruction and as a primary technique for small-volume augmentation. The regenerative properties of adipose-derived stem cells are being explored for wound healing, radiation damage repair, and tissue engineering. Ongoing debates include optimal processing methods (centrifugation vs filtration vs decantation), the role of platelet-rich plasma as an adjunct, standardization of cell-enrichment protocols, and the need for long-term (15-20 year) oncologic safety data. The field is moving toward fat grafting as a regenerative medicine platform rather than simply a volume replacement technique.